Evidence map›Paper›PMID 40034245›Full record

ReviewBladder cancer (Amsterdam, Netherlands)

Summary from the NCI clinical trials planning meeting on next generation of clinical trials in non-muscle invasive bladder cancer

Andrea Apolo, Brian C Baumann, Hikmat Al-Ahmadie, Leslie Ballas, Rick Bangs, Kenneth Brothers, Stephanie Cooper Greenberg, Scott Delacroix, James J Dignam, Jason A Efstathiou and 22 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Bladder cancer (Amsterdam, Netherlands). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

32 authors.

Andrea ApoloGenitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Brian C BaumannDepartment of Radiation Oncology, Springfield Clinic, Springfield, IL, USA.
Hikmat Al-AhmadieDepartment of Pathology and Laboratory Medicine, Genitourinary Pathology Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID https://orcid.org/0000-0002-2938-6627
Leslie BallasDepartment of Radiation Oncology, Cedars Sinai Medical Center, Los Angeles, CA, USA.
Rick BangsPatient Advocate, Bladder Cancer Advocacy Network, Bethesda, MD, USA.ORCID https://orcid.org/0000-0002-0706-8775
Kenneth BrothersPatient Advocate, National Cancer Institute Bladder Cancer Task Force, Rockville, MD, USA.
Stephanie Cooper GreenbergPatient Advocate, National Cancer Institute Bladder Cancer Task Force, Rockville, MD, USA.ORCID https://orcid.org/0009-0006-8067-4663
Scott DelacroixDepartment of Urology, Louisiana State University Health Science Center, New Orleans, New Orleans, LA, USA.
James J DignamDepartment of Public Health Sciences, University of Chicago, Chicago, IL, USA.
Jason A EfstathiouDepartment of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Adam S FeldmanDepartment of Urology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Jared C FosterDivision of Cancer Treatment and Diagnosis, National Cancer Institute, NIH, Bethesda, MD, USA.
Noah M HahnDepartments of Oncology and Urology, Johns Hopkins University, Greenberg Bladder Cancer Institute, Baltimore, MD, USA.ORCID https://orcid.org/0000-0002-1016-9024
Emma HallClinical Trials and Statistics Unit, The Institute of Cancer Research, London, UK.ORCID https://orcid.org/0000-0001-5999-5020
Donna E HanselDivision of Pathology and Laboratory Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Jean Hoffman-CensitsDepartments of Oncology and Urology, Johns Hopkins University, Greenberg Bladder Cancer Institute, Baltimore, MD, USA.ORCID https://orcid.org/0000-0002-6970-6509
Ashish M KamatDepartment of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Sophia C KamranDepartment of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.ORCID https://orcid.org/0000-0001-9283-6515
Francesca KhaniDepartment of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, USA.
Seth P LernerScott Department of Urology, Dan L. Duncan Cancer Center, Baylor College of Medicine, Houston, TX, USA.
Robert LipmanPatient Advocate, Bladder Cancer Advocacy Network, Bethesda, MD, USA.ORCID https://orcid.org/0000-0002-5182-9412
Bhupinder MannCancer Therapy Evaluation Program, National Cancer Institute, NIH, Rockville, MD, USA.
David McConkeyDepartments of Oncology and Urology, Johns Hopkins University, Greenberg Bladder Cancer Institute, Baltimore, MD, USA.ORCID https://orcid.org/0000-0003-1971-0638
James McKiernanHerbert Irving Comprehensive Cancer Center, Columbia University, New York, NY, USA, Department of Urology, Columbia University, New York, NY, USA.
Tracy L RoseLineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA.
Angela B SmithDepartment of Urology, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA.
Catherine TangenSWOG Statistical Center, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Abdul Tawab AmiriCoordinating Center for Clinical Trials, National Cancer Institute, NIH, Bethesda, MD, USA.
Chana WeinstockCenter for Drug Evaluation and Research, U. S. Food and Drug Administration, Silver Spring, MD, USA.
Pamela J WestEmmes Company, Rockville, MD, USA.
Matthew I MilowskyLineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA.
Peter C BlackDepartment of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada.ORCID https://orcid.org/0000-0002-2919-7068

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
Translational Research Central ServicesP30CA006973 · NCI · JOHNS HOPKINS UNIVERSITY · PI Rosalie Wollett · 1985 to 2026
$208.6M
SWOG Network Group Operations Center of the NCTNU10CA180888 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI PRIMO N. LARA · 2014 to 2026
$152.1M
SWOG Statistics & Data Management Center complex - extension supplement for GY06U10CA180819 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Catherine M. Tangen · 2014 to 2026
$115.2M
Phase 1/2 Study of Modern Immunotherapy in BCG-Relapsing Urothelial Carcinoma of the Bladder - (ADAPT-BLADDER)R01CA235681 · NCI · JOHNS HOPKINS UNIVERSITY · PI HAHN, NOAH M · 2019 to 2024
$3.2M
Blood-based monitoring of bladder-sparing trimodality therapy for muscle-invasive bladder cancerR01CA259007 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI MIYAMOTO, DAVID T. · 2022 to 2025
$3.0M
NCI NIH HHS P30 CA006973NCI NIH HHS P30 CA008748NCI NIH HHS R01 CA235681NCI NIH HHS R01 CA259007NCI NIH HHS U10 CA180819NCI NIH HHS U10 CA180888
6 · The paper itself

Abstract

The National Cancer Institute organized a virtual Clinical Trials Planning Meeting (CTPM) on 'Defining the next generation of clinical trials with combination therapies in non-muscle invasive bladder cancer (NMIBC)' led by the Bladder Cancer Task Force of the NCI Genitourinary Cancers Steering Committee. The purpose of this meeting was to accelerate advances in clinical trials for patients with high-risk NMIBC. The meeting delivered a multidisciplinary expert consensus on optimal strategies for next-generation clinical trial designs in NMIBC with prioritization of combination therapies. Two clinical trial concepts were developed for potential implementation within the National Clinical Trials Network.

Indexed as

BCGclinical trialnon-muscle invasive bladder cancerradiation therapy

Identifiers

PMID40034245
PMCPMC11863732

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.